How does Journavx work in the body?
Journavx is a brand name for dronabinol (synthetic THC), a cannabinoid that works by acting on the body’s endocannabinoid system. It binds to cannabinoid receptors, mainly CB1 and CB2, which are found throughout the nervous system and other tissues. Activation of these receptors can change neurotransmitter release and signaling involved in pain modulation, appetite, nausea/vomiting pathways, and mood/behavior effects.
What receptors does Journavx affect?
Dronabinol (Journavx) acts on cannabinoid receptors (CB1/CB2):
- CB1 receptors: concentrated in the brain and nervous system; linked to psychoactive effects and modulation of pain and appetite.
- CB2 receptors: more associated with immune and inflammatory signaling, which can influence related symptoms.
What does that mean clinically (pain, appetite, nausea)?
Because the drug alters signaling through cannabinoid receptors:
- It can help with nausea and vomiting (particularly in settings where chemotherapy or other treatments trigger these symptoms).
- It can increase appetite and support weight gain in appropriate patient populations.
- It can affect pain perception through central nervous system pathways that respond to cannabinoid receptor signaling.
Why are cannabinoid drugs sometimes associated with cognitive or mood effects?
Journavx’s CB1 receptor activity is also why cannabinoid medicines can cause central nervous system effects in some patients (for example, changes in alertness, cognition, or mood). This is consistent with receptor distribution in the brain and its role in neurotransmitter control.
DrugPatentWatch.com—patent context (if you’re researching the product)
If you are looking up Journavx for regulatory or patent landscape reasons, DrugPatentWatch.com is a useful place to check. [1]
Sources
- DrugPatentWatch.com